What one share of Mannkind holds
We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Mannkind’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.26 |
|---|---|
| Profit | −$0.14 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$0.06 |
| Cash and investments | $0.17 |
| Debt | $1.03 |
| Book value | −$0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | — | −$10.35 | $0.89 | −$9.54 | — | −$2.78 |
| 2010 | — | −$7.50 | $0.42 | −$6.96 | — | −$7.26 |
| 2011 | — | −$6.60 | $0.28 | −$5.36 | — | −$11.92 |
| 2012 | — | −$4.68 | $0.02 | −$3.33 | — | −$1.93 |
| 2013 | — | −$3.20 | $0.13 | −$2.28 | — | −$0.42 |
| 2014 | — | −$2.57 | $0.31 | −$0.26 | — | −$0.91 |
| 2015 | — | −$4.54 | $0.13 | −$0.83 | — | −$4.09 |
| 2016 | $1.90 | $1.36 | $0.01 | −$0.86 | — | −$1.92 |
| 2017 | $0.11 | −$1.13 | — | — | — | −$1.80 |
| 2018 | $0.19 | −$0.60 | $0.00 | −$0.26 | — | −$0.94 |
| 2019 | $0.32 | −$0.27 | $0.01 | −$0.47 | — | −$0.90 |
| 2020 | $0.29 | −$0.26 | $0.00 | −$0.13 | — | −$0.75 |
| 2021 | $0.30 | −$0.32 | $0.05 | −$0.29 | — | −$0.83 |
| 2022 | $0.39 | −$0.34 | $0.03 | −$0.34 | — | −$0.95 |
| 2023 | $0.75 | −$0.04 | $0.16 | −$0.03 | — | −$0.91 |
| 2024 | $1.01 | $0.10 | $0.03 | $0.12 | — | −$0.26 |
| 2025 | $1.11 | $0.02 | $0.01 | $0.04 | — | −$0.17 |
Common questions about Mannkind
How much does one share of Mannkind earn?
Over the last 12 months, Mannkind lost $0.14 for each share on $1.26 of sales.
Does Mannkind pay a dividend?
Mannkind didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Mannkind’s book value per share?
Mannkind’s book value is negative (−$0.22 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Mannkind have?
Each share of Mannkind has $0.17 of cash and investments and $1.03 of debt, as of June 30, 2026.
What is Mannkind’s free cash flow per share?
−$0.06 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Mannkind bought back shares?
Mannkind’s share count rose about 1377% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.